Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Valneva SE
Most of the money raised by biotech companies to address chronic hepatitis B has resulted in failed programs. But wait, a glimmer of light from yonder pharma breaks.
The UK biotech looks to have reached the end of the road, despite some encouraging signs from its microbiome-based pipeline.
Roivant and Pfizer launched Priovant to develop the oral drug brepocitinib for dermatomyositis, lupus and other autoimmune diseases, but Roivant also cut programs to extend its cash runway.
Private Company Edition: While the tough state of financing for publicly traded drug developers continues, venture capital firms and private biopharma companies revealed billions of dollars in new VC funds and start-up financings, including $100m-plus mega-rounds for Tessa, Alladapt and ImCheck.
- Contract Research, Toxicology Testing-CRO
- Drug Delivery
- Drug Discovery Tools
- Synthesis Technologies, Production Processes
- Other Names / Subsidiaries
- BliNK Biomedical SAS
- Crucell Sweden AB
- Iomai Corporation
- Intercell USA, Inc.
- Intercell AG, Vivalis